New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA Approves Controversial New Alzheimer’s Drug

Aduhelm received “accelerated approval” despite differing perspectives from the expert community.

A recent CNN Health article discussed the FDA’s approval of Biogen’s experimental drug for early phases of Alzheimer’s disease. The drug, aducanumab, was developed to treat patients with mild cognitive impairment and slow the progression of the neurodegenerative disease, and not just the symptoms. However, an FDA advisory committee determined last year that there wasn’t enough support that the treatment is actually effective.

The drug, also known as Aduhelm, received “accelerated approval,” which means Biogen is required to conduct “post-approval studies” to confirm the treatments have the clinical benefits they claim. If these studies, known as Phase 4 confirmatory trials, don’t fail to do so, the FDA could remove the drug from the market. In addition to the benefits of the drug being under scrutiny, so is the price, which wholesales for $4,312 per infusion, or $56k/year.

How Can You Honor a Leader?
Induction into the Packaging & Processing Hall of Fame is the highest honor in our industry. Submit your leader to be considered for the Class of 2024 now through June 10th. New members will be inducted at PACK EXPO International in Chicago
Read More
How Can You Honor a Leader?
Discover Our Content Hub
Access Packaging World's free educational content library!
Read More
Discover Our Content Hub